Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
AuthorsBrooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran HT, Papadimitrakopoulou VA,
JournalCancer
PubMed ID21523723
'Treatment options for patients with advanced head and neck squamous cell carcinoma (HNSCC) are scarce. This phase 2 study was conducted to evaluate the safety, tolerability, pharmacokinetics, and efficacy of dasatinib in this setting. Patients with recurrent and/or metastatic HNSCC after platinum-based therapy were treated with dasatinib either orally or ... More
Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy.
AuthorsOliver JM, Tarleton CA, Gilmartin L, Archibeque T, Qualls CR, Diehl L, Wilson BS, Schuyler M,
JournalInt Arch Allergy Immunol
PubMed ID19844128
Treating asthmatics with the humanized IgE-scavenging antibody, omalizumab (rhuMAb-E25, Xolair, reduces airways inflammation and asthma symptoms. Previously, omalizumab was shown to cause a dramatic and reversible loss of cell surface high-affinity IgE receptors, FcepsilonRI, from the peripheral blood basophils of asthmatics. The consequences of receptor loss for the FcepsilonRI-mediated synthesis ... More